Description of the portfolio company
ArkeaBio is an Boston-based start-up that is developing a vaccine to decrease methane emissions from livestock. Emissions from the sector are significant (~6% of total greenhouse gas emissions) but the current mitigants either have a long time to market, target only a small population of animals, or are costly.
Investment rationale
In our efforts to lower the climate impact of today’s food system, we target both alternatives for animal proteins and solutions that make animal protein production more sustainable without negatively impacting animal welfare. In our search for solutions that can lower the footprint of livestock farming and be applicable across all feeding systems, ArkeaBio emerged as a game-changing solution. Their cost-effective, easy-to-deploy and high-quality vaccines have the potential to be a critical tool as part of the broader set of solutions that enable the food systems transition.